Nicholas Coupe, MBBS, PhD, Provides Update on Phase 2 Study of IMM60 in Advanced Melanoma/NSCLC
Source: Cancer Network, August 2022
Nicholas Coupe, MBBS, PhD, discusses promising preliminary findings from a phase 1/2 study assessing the use of IMM60 in patients with advanced melanoma and non–small cell lung cancer.
An initial readout of an ongoing phase 1/2 study (ISRCTN80472712) from the 2022 American Society of Clinical Oncology Annual Meeting indicated that treatment with IMM60 in patients with advanced melanoma and non–small cell lung cancer (NSCLC) yielded promising preliminary safety data, according to lead author Nick Coupe, MBBS, PhD.
Aside from reporting that no adverse effects occurred in the 5 patients who were treated, Coupe, a consultant medical oncologist at Churchill Hospital, highlighted a notable reduction in tumor volume for 1 patient and a mixed response in another. Although the work is early, he explained how the research may lay the groundwork for further research.